SYP-5
目录号 : GC32876
A HIF-1 inhibitor
Cas No.:1384268-04-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SYP-5 is an inhibitor of hypoxia-inducible factor-1 (HIF-1).1 It inhibits HIF-1 activity in a reporter assay when used at concentrations ranging from 0.1 to 100 ?M. SYP-5 (2, 10, and 50 ?M) reduces hypoxia- or VEGF-induced capillary tube formation in human umbilical vein endothelial cells (HUVECs). It inhibits the migration and invasion of Hep3B hepatocellular carcinoma and BCaP-37 breast cancer cells in a concentration-dependent manner.
1.Wang, L.-H., Jiang, X.-R., Yang, J.-Y., et al.SYP-5, a novel HIF-1 inhibitor, suppresses tumor cells invasion and angiogenesisEur. J. Pharmacol.791560-568(2016)
Cell experiment: | The cells (1×105 cells/mL) are seeded into 96-well culture plates. After overnight ncubation, the cells are treated with various concentrations of SYP-5 (2, 10, 50 μM) for 24 h. Then 10μLMTT) solution (2.5 mg/mL in PBS) is added to each well, and the plates are incubated for additional 4 h at 37°C. After centrifugation (2500 rpm, 10 min), the medium containing MTT is aspirated, and 100 μL DMSO is added. The optical density of each well is measured at 570 nm with a SpectraMax Paradigm Reader[1]. |
References: [1]. Wang LH, et al. SYP-5, a novel HIF-1 inhibitor, suppresses tumor cells invasion and angiogenesis. Eur J Pharmacol. 2016 Nov 15;791:560-568. | |
| Cas No. | 1384268-04-5 | SDF | |
| Canonical SMILES | O=C(C1=C(O)C(C=CC(C)(C)O2)=C2C=C1)/C=C/C3=CC=CS3 | ||
| 分子式 | C18H16O3S | 分子量 | 312.38 |
| 溶解度 | DMSO : 33.33 mg/mL (106.70 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2012 mL | 16.0061 mL | 32.0123 mL |
| 5 mM | 0.6402 mL | 3.2012 mL | 6.4025 mL |
| 10 mM | 0.3201 mL | 1.6006 mL | 3.2012 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet